The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334.

Summary

This is open-label, multicenter, Phase I/II study is designed to evaluate the Safety and tolerability and Efficacy of IBI334 Monotherapy in participants with advanced solid tumors.

Timeline

Start

2023-08-09

Primary completion

2025-03-20

Completion

2025-03-20

Publications

• Guan J, Chia T, Li B, Zhu T, Liao Z, Deng J, Fu F, Wu W, Liu C, Liu Y, Li N, Yue L, Cao L, Lu J, Zhu M, Ling X, Zheng H, Lin S, Li L, Zhou S, He K. B7-H3-mediated cis-inhibition of EGFR by a tumor-selective bispecific antibody enhances anti-tumor efficacy and minimizes toxicities. Nat Commun. 2026 Feb 24;17(1):3113. doi: 10.1038/s41467-026-69703-7.

Drugs

Indications